ified classification allows patients with ypStage II locally advanced rectal cancer to be clearly divided into two groups: responders and nonresponders.
A Modified Classification of Prognostic Factors

Introduction
Multidisciplinary treatment including preoperative radiotherapy is the global standard for T3, N0 or T any , N1-2, or T4 rectal cancer and significantly decreases local recurrence [1] [2] [3] [4] . However, the European Society for Medical Oncology (ESMO) guidelines [5] claim that clinical T3a or T3b, N0 cancer of the middle or higher rectum has a good outcome and can therefore be treated by surgery alone.
The histologic response to preoperative chemoradiotherapy (CRT) in the radiation field has been reported to be closely related to outcomes. Patients who have posttreatment pathological complete regression, a marked decrease in tumor volume, or downstaging of T or N stage have been shown to have significantly better disease-free survival (DFS) and overall survival (OS) than patients without these findings [6] [7] [8] [9] [10] . However, ypStage II disease includes patients who initially have pT3-T4, N1 disease and show a good response  to treatment, resulting in downstaging, patients who initially have pT3-T4, N0 disease who respond to treatment  without downstaging, and patients who initially have  pT3-T4, N0 disease and show a poor response to treatment. We therefore hypothesized that a new classification more closely related to outcomes could be developed by dividing patients with ypStage II disease into two groups: those with a good histologic response and those with a poor histologic response. We thus designed a modified classification based on the posttreatment pathological stage (ypStage) and tumor regression grade (TRG).
Subjects and Methods
Between 2007 and 2015, total mesorectal excision surgery combined with preoperative CRT was used to treat 198 patients with histologically proven adenocarcinoma of the middle or lower rectum who had a preoperative diagnosis of clinical stage (cStage) II or stage III disease according to the TNM classification.
The initial evaluation included digital examination of the rectum, colonoscopy, barium enema, computed tomography of the chest, abdomen, and pelvis, endorectal ultrasonography, and magnetic resonance imaging of the pelvis.
Chemoradiotherapy
Preoperative radiotherapy was performed with 18-MV X-ray beams delivered by a linear accelerator (Clinac 2100C; Varian Medical Systems, Inc., Palo Alto, CA, USA) using a four-field technique. Irradiation was performed once (1.8 or 2 Gy) daily to a total dose of 40-45 Gy. Total mesorectal excision surgery was done 6-8 weeks (range, 30-65 days) after the completion of irradiation.
Concomitant chemotherapy with oral uracil-tegafur (400 mg/ m 2 ) or oral S-1 (80 mg/m 2 ) was started at the same time as radiotherapy. Oral uracil-tegafur was simultaneously given with radiotherapy on 5 weekdays, followed by a 2-day rest on weekends. This cycle was repeated during irradiation. Oral S-1 (80 mg/m 2 ) was simultaneously started with radiotherapy. S-1 was given for 2 consecutive weeks, followed by a 1-week rest, and was then given for another 2 weeks [11, 12] .
Histologic regression was assessed using the Mandard TRG [13] as follows: TRG 1, complete regression; TRG 2, presence of rare residual cancer cells; TRG 3, fibrosis outgrowing residual cancer cells; TRG 4, residual cancer cells outgrowing fibrosis; and TRG 5, absence of regression.
We designed a modified classification based on the TRG that classified patients with ypStage II disease into two groups. Patients with TRG 2 were classified as ypTRGstage IIA, and those with TRG 3 or 4 were classified as ypTRGstage IIB ( Table 1 ) .
Statistical Analysis
Statistical analysis was performed using SPSS for Windows, version 23 (IBM Japan, Ltd., Tokyo, Japan). Actuarial survival curves were calculated according to the Kaplan-Meier method. The probabilities of DFS and OS were determined by log-rank analysis. A Cox proportional hazards model was used to adjust comparisons for clinicopathological variables. p values <0.05 were considered to indicate statistical significance. Table 2 shows the patient characteristics. There were 150 men and 48 women with a median age of 64 years. Overall, 85 patients had clinical stage II disease and 113 had clinical stage III disease. The chemotherapeutic drugs administered concurrently with preoperative radiotherapy were S-1 in 153 patients (77.3%) and uraciltegafur in 45 patients (22.7%). Sphincter-preserving surgery was performed in 147 patients (74.2%). Before CRT, 96.5% of the patients had clinical T3 or T4 disease, and 57.1% had clinical N1 or cN2 disease. After CRT, however, the proportion of patients with pathological T3 or T4 disease decreased to 51.5%, and the proportion of patients with pathological N1 or N2 disease decreased to 22.7%.
Results
Patient and Tumor Characteristics
Pathological complete response (pCR) was found in 31 patients (15.7%). One patient had complete regression (TRG 1) of the primary lesion, but was pathologically node-positive (pN+). Among the 40 patients with pathological T0 disease, 8 had carcinoma in situ (Tis).
The 
Survival Analysis
The median follow-up was 52 months (range, 1-168). The 5-year DFS was 71%, and the 5-year OS was 85%. Recurrence was found in 48 patients (24.2%). The initial site of recurrence was locoregional in 6 patients (3.0%), the liver in 17 patients (8.6%), the lung in 19 patients (9.6%), and distant lymph nodes in 6 patients (3.0%).
The 5-year DFS rate according to the TRG was as follows: TRG 1, 89%; TRG 2, 76%; TRG 3, 67%; and TRG 4, 59%. The 5-year OS rate according to the TRG was as follows: TRG 1, 96%; TRG 2, 82%; TRG 3, 84%; and TRG 4, 83%. Marked tumor regression (TRG 1 or 2) was contrasted with TRG 3 or 4. The DFS rate was significantly higher in patients with TRG 1 or 2 than in those with TRG 3 or 4 ( p = 0.014). The OS rate did not differ between these groups ( p = 0.744).
The 5-year DFS rate according to the ypStage was as follows: ypStage 0, 88%; ypStage I, 78%; ypStage II, 64%; and ypStage III, 60% ( p = 0.002) ( Fig. 1 a) . The 5-year OS rate according to ypStage was as follows: ypStage 0, 97%; ypStage I, 86%; ypStage II, 83%; and ypStage III, 80% ( p = 0.220) ( Fig. 1 b) .
The 5-year DFS rate according to the ypTRGstage was as follows: ypTRGstage I, 83%; ypTRGstage IIA, ( Fig. 2 a) . The 5-year OS rate according to the ypTRGstage was as follows: ypTRGstage I, 90%; ypTRGstage IIA, 100%; ypTRGstage IIB, 77%; and ypTRGstage III, 80% ( p = 0.029) ( Fig. 2 b) . When ypStage was compared with ypTRGstage, the 5-year DFS rate in ypTRGstage IIA did not differ from The 65 patients with ypStage II, comprising the largest subgroup of patients according to ypStage, could be classified into 16 patients with ypTRGstage IIA and a good prognosis and 49 patients with ypTRGstage IIB and a poor prognosis.
Prognostic Factors Affecting Survival TRG 1 and 2, ypStage 0 and I, and ypTRGstage 0, I, and IIA were collectively considered to indicate a good response. Cox univariate analysis was performed to assess the relations of these variables to DFS. DFS correlated with ypT, post-CRT pathological nodal status (ypN), lymphatic invasion, venous invasion, TRG, ypStage, and ypTRGstage ( Table 3 ).
Significant factors in the Cox univariate analysis were included in multivariate analysis. The results showed that ypT, ypN, and ypStage correlated with each other. Since ypT, ypN, TRG, and ypTRGstage correlated with each other, three types of multivariate analyses were performed ( Table 4 ). The results showed that ypT, ypStage, and ypTRGstage were independent risk factors for DFS. The hazard ratio of ypTRGstage was 2.876 (95% confidence interval, 1.510-5.477), which was greater than the hazard ratio of ypStage (2.274; 95% confidence interval, 1.152-4.488).
Cox univariate analysis showed that OS was related to ypT, lymphatic invasion, ypStage, and ypTRGstage. Multivariate analysis showed that lymphatic invasion was an independent risk factor for OS ( Table 5 ) .
Discussion
Previous studies have reported that post-CRT ypT, ypN, ypStage, and histologic response (TRG) are related to oncologic outcomes [6, 8, 10, [14] [15] [16] [17] [18] [19] [20] [21] . A four-level subclassification of the depth of extramuscular invasion has been proposed for pathological T stage (pT stage) [22] . In patients who are treated by surgery alone, DFS differs according to the subclassification of pT, but does not differ in patients who have received preoperative CRT. Therefore, pT has been reported not to be a prognostic factor [23, 24] .
The TRG has been widely used to evaluate the histologic response to preoperative CRT. Quah et al. [25] reported that ypStage was more strongly associated with DFS than was TRG in 342 patients with rectal cancer who received preoperative CRT.
Patients with pCR [6, 8, 16, 18, [26] [27] [28] and those with good tumor regression even in the absence of pCR [8, 16, 17, 21, 26, [28] [29] [30] [31] have been reported to have good outcomes. Agarwal et al. [28] studied 251 patients with locally advanced rectal adenocarcinoma who received preoperative CRT and found that recurrence-free survival did not differ between patients with pCR and those with nearly complete response (residual cancer cells ≤ 5%). Guillem et al. [8] studied 297 patients with rectal cancer who received preoperative CRT and reported that the survival rate was significantly higher in patients with pCR or nearly pCR ( ≥ 95% tumor response) than in patients with other responses.
On the basis of these results, evaluation methods combining ypStage and TRG have been studied to identify better prognostic factors. Cui et al. [30] studied 329 patients with clinical stage II or III rectal adenocarcinoma who received preoperative CRT and developed a modified T stage classification metric (M-TTRG) that categorized patients into five subgroups on the basis of ypT stage and TRG. This system was combined with ypN stage to develop a modified ypTNM staging system that categorizes patients into seven subgroups. However, this system is very complex.
Some patients with ypStage II histologically have a nearly pCR without downstaging owing to the presence of small amounts of cancer cells in extramuscular tissue. The ypTRGstage that we proposed allowed patients with ypStage II to be classified into two subgroups: patients with ypStage II who have a good response to treatment with no downstaging and patients with ypStage II who have a poor response to treatment. This classification of responders and nonresponders was more closely related to outcomes.
In patients who have received neoadjuvant chemotherapy, the indications for and regimens of postoperative adjuvant chemotherapy remain controversial [32, 33] . In the present study, the rate of adjuvant chemotherapy was 44% in ypStage 0 or I disease, 60% in ypStage II or III disease, 45% in ypTRGstage I or IIA disease, and 62% in ypTRGstage IIB or III disease. The rates of adjuvant chemotherapy were significantly higher in ypStage II or III disease ( p = 0.040) and in ypTRGstage IIB or III disease ( p = 0.029).
Our study was retrospective and has several important limitations. It was performed in a single hospital and included only 198 patients. Further multicenter studies of larger number of patients are needed to verify our results.
The ypTRGstage consists of four classes. The survival rate did not differ between ypTRGstage I and IIA, associated with a good response, or between ypTRGstage IIB and III, associated with a poor response. Further studies are therefore needed to determine whether patients who 
Conclusions
A modified classification based on the combination of ypStage and TRG as prognostic factors allowed patients with ypStage II locally advanced rectal cancer who received neoadjuvant CRT to be classified into good and poor responders. This classification is a useful straightforward method for predicting outcomes.
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